Extract from the Register of European Patents

EP About this file: EP2874649

EP2874649 - CELLS FOR PRODUCING RECOMBINANT IDURONATE-2-SULFATASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.11.2019
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  30.11.2018
FormerGrant of patent is intended
Status updated on  27.11.2018
FormerExamination is in progress
Status updated on  18.07.2018
FormerGrant of patent is intended
Status updated on  06.03.2018
FormerExamination is in progress
Status updated on  14.07.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK
published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Shire Human Genetic Therapies, Inc.
300 Shire Way
Lexington MA 02421 / US
[2016/47]
Former [2015/22]For all designated states
Shire Human Genetic Therapies, Inc.
300 Shire Way
Lexington, MA 02421 / US
Inventor(s)01 / BOLDOG, Ferenc
300 Shire Way
Lexington, Massachusetts 02421 / US
02 / HEARTLEIN, Michael
167 Reed Farm Road
Boxborough, Massachusetts 01719 / US
 [2015/22]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2015/22]
Application number, filing date13810018.528.06.2013
[2019/01]
WO2013US48571
Priority number, dateUS201261666719P29.06.2012         Original published format: US 201261666719 P
[2015/22]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2014005019
Date:03.01.2014
Language:EN
[2014/01]
Type: A2 Application without search report 
No.:EP2874649
Date:27.05.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 03.01.2014 takes the place of the publication of the European patent application.
[2015/22]
Type: B1 Patent specification 
No.:EP2874649
Date:02.01.2019
Language:EN
[2019/01]
Search report(s)International search report - published on:US27.02.2014
(Supplementary) European search report - dispatched on:EP04.04.2016
ClassificationIPC:A61K38/46, C07K1/00, C12P21/06
[2015/22]
CPC:
C12N9/16 (EP,CN,EA,IL,KR,US); C12N15/85 (CN,EA,IL,KR); A61K38/46 (EA,IL,KR);
C12N9/0051 (EA,IL,KR); C12P21/06 (EA,IL,KR); C12Y108/99 (EA,IL,KR);
C12Y301/06013 (EP,CN,EA,IL,KR,US); C12N2800/107 (CN,EA,IL) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/22]
Extension statesBA20.01.2015
ME20.01.2015
TitleGerman:VERFAHREN ZUR HERSTELLUNG REKOMBINANTER IDURONAT-2-SULFATASE[2015/22]
English:CELLS FOR PRODUCING RECOMBINANT IDURONATE-2-SULFATASE[2015/22]
French:CELLULES POUR L'OBTENTION D'IDURONATE-2-SULFATASE RECOMBINANTE[2015/22]
Entry into regional phase20.01.2015National basic fee paid 
20.01.2015Search fee paid 
20.01.2015Designation fee(s) paid 
20.01.2015Examination fee paid 
Examination procedure20.01.2015Examination requested  [2015/22]
01.11.2016Amendment by applicant (claims and/or description)
18.07.2017Despatch of a communication from the examining division (Time limit: M06)
25.01.2018Reply to a communication from the examining division
07.03.2018Communication of intention to grant the patent
17.07.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
17.07.2018Fee for grant paid
17.07.2018Fee for publishing/printing paid
27.11.2018Information about intention to grant a patent
27.11.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  18.07.2017
Opposition(s)03.10.2019No opposition filed within time limit [2019/50]
Fees paidRenewal fee
29.06.2015Renewal fee patent year 03
27.06.2016Renewal fee patent year 04
27.06.2017Renewal fee patent year 05
22.06.2018Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU28.06.2013
AL02.01.2019
AT02.01.2019
CY02.01.2019
CZ02.01.2019
DK02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
MK02.01.2019
MT02.01.2019
NL02.01.2019
PL02.01.2019
RO02.01.2019
RS02.01.2019
SE02.01.2019
SI02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
NO02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
IE28.06.2019
LU28.06.2019
BE30.06.2019
CH30.06.2019
LI30.06.2019
[2022/31]
Former [2021/34]HU28.06.2013
AL02.01.2019
AT02.01.2019
CY02.01.2019
CZ02.01.2019
DK02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
MT02.01.2019
NL02.01.2019
PL02.01.2019
RO02.01.2019
RS02.01.2019
SE02.01.2019
SI02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
NO02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
IE28.06.2019
LU28.06.2019
BE30.06.2019
CH30.06.2019
LI30.06.2019
Former [2021/32]HU28.06.2013
AL02.01.2019
AT02.01.2019
CY02.01.2019
CZ02.01.2019
DK02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
NL02.01.2019
PL02.01.2019
RO02.01.2019
RS02.01.2019
SE02.01.2019
SI02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
NO02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
IE28.06.2019
LU28.06.2019
BE30.06.2019
CH30.06.2019
LI30.06.2019
Former [2021/26]AL02.01.2019
AT02.01.2019
CY02.01.2019
CZ02.01.2019
DK02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
NL02.01.2019
PL02.01.2019
RO02.01.2019
RS02.01.2019
SE02.01.2019
SI02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
NO02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
IE28.06.2019
LU28.06.2019
BE30.06.2019
CH30.06.2019
LI30.06.2019
Former [2020/25]AL02.01.2019
AT02.01.2019
CZ02.01.2019
DK02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
NL02.01.2019
PL02.01.2019
RO02.01.2019
RS02.01.2019
SE02.01.2019
SI02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
NO02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
IE28.06.2019
LU28.06.2019
BE30.06.2019
CH30.06.2019
LI30.06.2019
Former [2020/21]AL02.01.2019
AT02.01.2019
CZ02.01.2019
DK02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
NL02.01.2019
PL02.01.2019
RO02.01.2019
RS02.01.2019
SE02.01.2019
SI02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
NO02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
IE28.06.2019
Former [2020/13]AL02.01.2019
AT02.01.2019
CZ02.01.2019
DK02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
NL02.01.2019
PL02.01.2019
RO02.01.2019
RS02.01.2019
SE02.01.2019
SI02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
NO02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
Former [2020/08]AL02.01.2019
AT02.01.2019
CZ02.01.2019
DK02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
NL02.01.2019
PL02.01.2019
RO02.01.2019
RS02.01.2019
SE02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
NO02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
Former [2019/52]AL02.01.2019
AT02.01.2019
CZ02.01.2019
DK02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
NL02.01.2019
PL02.01.2019
RO02.01.2019
RS02.01.2019
SE02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
NO02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
Former [2019/49]AL02.01.2019
AT02.01.2019
CZ02.01.2019
DK02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
NL02.01.2019
PL02.01.2019
RO02.01.2019
RS02.01.2019
SE02.01.2019
SK02.01.2019
BG02.04.2019
NO02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
Former [2019/48]AT02.01.2019
DK02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
NL02.01.2019
PL02.01.2019
RS02.01.2019
SE02.01.2019
BG02.04.2019
NO02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
Former [2019/46]AT02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
NL02.01.2019
PL02.01.2019
RS02.01.2019
SE02.01.2019
BG02.04.2019
NO02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
Former [2019/39]FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
NL02.01.2019
PL02.01.2019
RS02.01.2019
SE02.01.2019
BG02.04.2019
NO02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
Former [2019/38]FI02.01.2019
LT02.01.2019
NL02.01.2019
PL02.01.2019
SE02.01.2019
BG02.04.2019
NO02.04.2019
GR03.04.2019
PT02.05.2019
Former [2019/37]FI02.01.2019
LT02.01.2019
NL02.01.2019
PL02.01.2019
SE02.01.2019
NO02.04.2019
GR03.04.2019
PT02.05.2019
Former [2019/35]FI02.01.2019
LT02.01.2019
NL02.01.2019
PL02.01.2019
SE02.01.2019
NO02.04.2019
PT02.05.2019
Former [2019/34]FI02.01.2019
LT02.01.2019
NL02.01.2019
SE02.01.2019
NO02.04.2019
PT02.05.2019
Former [2019/33]FI02.01.2019
LT02.01.2019
NL02.01.2019
NO02.04.2019
PT02.05.2019
Former [2019/30]NL02.01.2019
Documents cited:Search[I]   COSMA M P ET AL: "The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases", 16 May 2003, CELL, CELL PRESS, US, PAGE(S) 445 - 456, ISSN: 0092-8674, XP001155603 [I] 1-12 * page 450, column l, paragraph 2 * * page 452, column r, lines 9-12, paragraph 3 * * page 453, column r, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/S0092-8674(03)00348-9
International search[X] WO2004072275  (TRANSKARYOTIC THERAPIES INC et al.)
 [X] WO2011044542  (ARMAGEN TECHNOLOGIES INC et al.) [X]
 [Y] WO2005113765   [Y]
by applicant  MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.